Information for consumers
Diabetic ketoacidosis (DKA) is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening and fatal ones, have occurred in patients taking SGLT2 inhibitors [INVOKANA
® (canagliflozin), FORXIGA
® (dapagliflozin), XIGDUO
® (dapagliflozin/metformin), JARDIANCE
TM (empagliflozin)] for type 1 and type 2 diabetes.
A number of these cases have been unusual, with patients having blood sugar levels that are not as high as typically expected in DKA, which can lead to a delay in diagnosis and treatment.
Patients taking any of these medicines should be aware of the symptoms of DKA, including loss of appetite, nausea or vomiting, stomach pain, feeling very thirsty, rapid breathing, confusion, feeling unusual tiredness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat.
Patients should immediately seek medical advice if they develop any of these symptoms. Patients should also inform their healthcare professional about medical issues or factors (see below) that may predispose them to ketoacidosis.
SGLT2 inhibitors are NOT indicated for treatment of type 1 diabetes mellitus and should not be used in type 1 diabetes.
Information for health care professionals
Before initiating treatment with SGLT2 inhibitors, factors in the patient history that may predispose to ketoacidosis should be considered. These factors include:
-
patients on a very low carbohydrate diet (as the combination may further increase ketone body production),
-
an acute serious illness,
-
pancreatic disorders suggesting insulin deficiency (e.g., type 1 diabetes, history of pancreatitis or pancreatic surgery),
-
sudden insulin dose reduction (including insulin pump failure),
-
alcohol abuse,
-
conditions that lead to severe dehydration,
-
hospitalization for major surgery or serious medical illness.
SGLT2 inhibitors should be used with caution in these patients. In addition, patients should be informed of these risk factors.
SGLT2 inhibitors should not be used in patients with a history of DKA.
A substantial proportion of the cases concerned off-label use in patients with type 1 diabetes. Prescribers are reminded that type 1 diabetes is
NOT an approved indication for SGLT2 inhibitors.
Patients on SGLT2 inhibitors should be tested for ketones when they present with symptoms of acidosis in order to prevent delayed diagnosis and patient management. If ketoacidosis is suspected, treatment with SGLT2 inhibitors should be discontinued.
Prescribers should inform patients of signs and symptoms of metabolic acidosis and advise them to immediately seek medical advice if they develop such signs and symptoms.
Action taken by Health Canada
This communication is a follow-up to an
Information Update published by Health Canada on June 22, 2015. Health Canada is currently working with the manufacturers to update the Canadian Product Monograph to reflect this safety information.